Denis Chem Lab [DENISCHEM] vs Suven Life Sciences [SUVEN] Detailed Stock Comparison
Denis Chem Lab
BSE
Loading...
Suven Life Sciences
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Denis Chem Lab wins in 9 metrics, Suven Life Sciences wins in 8 metrics, with 0 ties. Denis Chem Lab appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Denis Chem Lab | Suven Life Sciences | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 15.50 | -28.01 | Suven Life Sciences |
| Price-to-Book Ratio | 1.56 | 40.49 | Denis Chem Lab |
| Debt-to-Equity Ratio | 0.01 | 0.00 | Suven Life Sciences |
| PEG Ratio | 0.83 | -0.34 | Suven Life Sciences |
| EV/EBITDA | 7.17 | -23.32 | Suven Life Sciences |
| Profit Margin (TTM) | 43.34% | 84.44% | Suven Life Sciences |
| Operating Margin (TTM) | 6.45% | -2,791.92% | Denis Chem Lab |
| EBITDA Margin (TTM) | 6.45% | N/A | N/A |
| Return on Equity | 9.49% | -146.15% | Denis Chem Lab |
| Return on Assets (TTM) | 7.19% | -118.91% | Denis Chem Lab |
| Free Cash Flow (TTM) | $44.64M | $-1.91B | Denis Chem Lab |
| Dividend Yield | 4.03% | N/A | N/A |
| 1-Year Return | -37.30% | 46.77% | Suven Life Sciences |
| Price-to-Sales Ratio (TTM) | 0.79 | 641.26 | Denis Chem Lab |
| Enterprise Value | $1.36B | $43.40B | Suven Life Sciences |
| EV/Revenue Ratio | 0.79 | 577.38 | Denis Chem Lab |
| Gross Profit Margin (TTM) | 43.24% | 100.00% | Suven Life Sciences |
| Revenue per Share (TTM) | $125 | $0 | Denis Chem Lab |
| Earnings per Share (Diluted) | $6.10 | $-8.15 | Denis Chem Lab |
| Beta (Stock Volatility) | N/A | 0.86 | N/A |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Denis Chem Lab vs Suven Life Sciences Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Denis Chem Lab | 1.25% | 1.53% | -3.09% | -4.63% | -0.83% | -43.99% |
| Suven Life Sciences | 0.80% | -0.17% | -3.10% | -15.83% | 58.82% | 63.15% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Denis Chem Lab | -37.30% | 18.43% | 136.13% | 102.17% | 314.68% | 314.68% |
| Suven Life Sciences | 46.77% | 186.97% | 307.88% | -25.87% | 594.28% | 3,728.07% |
News Based Sentiment: Denis Chem Lab vs Suven Life Sciences
Denis Chem Lab
News based Sentiment: NEGATIVE
September was a challenging month for Denis Chem Lab, marked by continued stock underperformance and declining profitability ratios despite standard corporate governance events like the AGM and dividend approval. While not a crisis, the lack of positive catalysts and ongoing negative trends create a concerning investment picture.
Suven Life Sciences
News based Sentiment: POSITIVE
The month of October 2025 saw Suven Life Sciences benefit from both company-specific gains and a broader pharmaceutical rally, indicating a positive trend for the company. The Pfizer agreement acted as a catalyst for this positive movement, suggesting a favorable market environment.
Performance & Financial Health Analysis: Denis Chem Lab vs Suven Life Sciences
| Metric | DENISCHEM | SUVEN |
|---|---|---|
| Market Information | ||
| Market Cap | ₹1.36B | ₹48.20B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 5,862 | 185,019 |
| 90 Day Avg. Volume | 7,716 | 147,095 |
| Last Close | ₹95.75 | ₹208.70 |
| 52 Week Range | ₹87.99 - ₹180.00 | ₹102.50 - ₹299.99 |
| % from 52W High | -46.81% | -30.43% |
| All-Time High | ₹232.90 (Jun 17, 2024) | ₹338.50 (Apr 13, 2015) |
| % from All-Time High | -58.89% | -38.35% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.05% | 0.86% |
| Quarterly Earnings Growth | 0.05% | 0.86% |
| Financial Health | ||
| Profit Margin (TTM) | 0.43% | 0.84% |
| Operating Margin (TTM) | 0.06% | -27.92% |
| Return on Equity (TTM) | 0.09% | -1.46% |
| Debt to Equity (MRQ) | 0.01 | 0.00 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹61.21 | ₹5.04 |
| Cash per Share (MRQ) | ₹0.61 | ₹2.75 |
| Operating Cash Flow (TTM) | ₹105.01M | ₹-1,590,282,000 |
| Levered Free Cash Flow (TTM) | ₹80.76M | ₹-1,607,450,000 |
| Dividends | ||
| Last 12-Month Dividend Yield | 4.03% | N/A |
| Last 12-Month Dividend | ₹4.00 | ₹0.00 |
Valuation & Enterprise Metrics Analysis: Denis Chem Lab vs Suven Life Sciences
| Metric | DENISCHEM | SUVEN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 15.50 | -28.01 |
| Forward P/E | N/A | 10.55 |
| PEG Ratio | 0.83 | -0.34 |
| Price to Sales (TTM) | 0.79 | 641.26 |
| Price to Book (MRQ) | 1.56 | 40.49 |
| Market Capitalization | ||
| Market Capitalization | ₹1.36B | ₹48.20B |
| Enterprise Value | ₹1.36B | ₹43.40B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.79 | 577.38 |
| Enterprise to EBITDA | 7.17 | -23.32 |
| Risk & Other Metrics | ||
| Beta | N/A | 0.86 |
| Book Value per Share (MRQ) | ₹61.21 | ₹5.04 |
Financial Statements Comparison: Denis Chem Lab vs Suven Life Sciences
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | DENISCHEM | SUVEN |
|---|---|---|
| Revenue/Sales | ₹432.76M | ₹18.67M |
| Cost of Goods Sold | ₹245.65M | ₹0 |
| Gross Profit | ₹187.11M | ₹18.67M |
| Research & Development | N/A | ₹414.88M |
| Operating Income (EBIT) | ₹32.00M | ₹-521.17M |
| EBITDA | ₹51.13M | ₹-501.49M |
| Pre-Tax Income | ₹33.15M | ₹-515.17M |
| Income Tax | ₹8.40M | ₹0 |
| Net Income (Profit) | ₹24.75M | ₹-515.17M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | DENISCHEM | SUVEN |
|---|---|---|
| Cash & Equivalents | ₹8.50M | ₹150.26M |
| Total Current Assets | ₹706.45M | ₹754.72M |
| Total Current Liabilities | ₹261.73M | ₹234.86M |
| Long-Term Debt | ₹4.53M | N/A |
| Total Shareholders Equity | ₹851.04M | ₹1.10B |
| Retained Earnings | ₹390.31M | ₹-6.01B |
| Property, Plant & Equipment | ₹39.91M | ₹756.69M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | DENISCHEM | SUVEN |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | DENISCHEM | SUVEN |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 5,862 | 185,019 |
| Average Daily Volume (90 Day) | 7,716 | 147,095 |
| Shares Outstanding | 13.88M | 218.07M |
| Float Shares | N/A | 67.61M |
| % Held by Insiders | 0.79% | 0.69% |
| % Held by Institutions | 0.00% | 0.02% |
Dividend Analysis & Yield Comparison: Denis Chem Lab vs Suven Life Sciences
| Metric | DENISCHEM | SUVEN |
|---|---|---|
| Last 12-Month Dividend | ₹4.00 | ₹0.00 |
| Last 12-Month Dividend Yield | 4.03% | N/A |
| 3-Year Avg Annual Dividend | ₹3.67 | ₹0.00 |
| 3-Year Avg Dividend Yield | 1.73% | N/A |
| 3-Year Total Dividends | ₹11.00 | ₹0.00 |
| Ex-Dividend Date | Sep 19, 2025 | N/A |